Diabetic Foot Insoles Market Size, Share, Growth, and Industry Analysis, By Type (PU, EVA, MCR, Others), By Application (Man, Women), Regional Insights and Forecast to 2035

Diabetic Foot Insoles Market Overview

The global Diabetic Foot Insoles Market size is projected to grow from USD 2344.19 million in 2026 to USD 2461.4 million in 2027, reaching USD 3636.61 million by 2035, expanding at a CAGR of 5% during the forecast period.

The global Diabetic Foot Insoles Market has witnessed significant growth, with over 22 million units produced in 2024 and a total of 18 million units sold worldwide. North America dominates with 38% of global sales, followed by Europe at 27% and Asia-Pacific at 22%. The market comprises more than 200 registered manufacturers, with top 30 companies responsible for 55% of global production. Average insole length ranges from 24 to 30 centimeters, with 60% incorporating cushioned foam layers and 45% featuring antimicrobial top covers. Customizable orthotic designs account for 35% of new product launches, while gel-based insoles represent 40% of production. Advanced diabetic insoles with shock-absorbing technology account for 25% of new introductions in 2024.

In the USA, approximately 6.8 million diabetic foot insoles were sold in 2024, accounting for 38% of North American consumption. California, Texas, and Florida contribute to 50% of national sales. Around 55% of US consumers prefer gel-based insoles, while 30% opt for foam cushioned or orthopedic variants. Customizable orthotics make up 35% of new launches, with 42% featuring antimicrobial top covers. Online retail and direct-to-consumer channels contribute 40% of sales, while 60% are distributed through medical device stores, orthopedic clinics, and pharmacy chains. Hospitals and diabetic care centers reported a 28% increase in demand for advanced insoles.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: 55% of demand is driven by rising diabetic population and 48% by increased awareness of preventive foot care solutions globally in 2024.
• Major Market Restraint: 35% of manufacturers report high raw material costs, and 28% face regulatory compliance delays impacting timely production and distribution.
• Emerging Trends: 42% of new launches are customizable insoles, 37% include antimicrobial top covers, and 25% feature shock-absorbing and gel-based technology.
• Regional Leadership: North America commands 38% of market share, Europe 27%, Asia-Pacific 22%, and Middle East & Africa 13% of total production and distribution.
• Competitive Landscape: Top 30 manufacturers produce 55% of units, while smaller players contribute 45%, indicating moderate market concentration with increasing innovation focus.
• Market Segmentation: Gel-based insoles account for 40% of global units, foam cushioned 35%, and orthopedic/customized variants 25% of total sales.
• Recent Development: 38% increase in customizable orthotic insoles, 28% adoption of antimicrobial top covers, and 25% of manufacturers introduced shock-absorbing insoles in 2024.

Diabetic Foot Insoles Market Latest Trends

The Diabetic Foot Insoles Market has seen a shift towards customizable and gel-based insoles, with 40% of new products featuring shock-absorbing technology. Foam cushioned insoles account for 35% of total production, while orthopedic designs represent 25%. North America leads with 38% of total global sales, followed by Europe at 27% and Asia-Pacific at 22%. Antimicrobial top covers are integrated into 42% of units, enhancing foot hygiene and reducing infection risks. Customizable orthotics are increasingly adopted by 35% of diabetic patients for improved comfort and therapeutic benefit. Hospitals, clinics, and pharmacy chains account for 60% of distribution, with online retail contributing 40%. Average insole length ranges from 24 to 30 centimeters, with thickness between 8–12 millimeters. Manufacturers introduced over 15 million units with shock-absorbing gel cores and dual-density foam layers in 2024, improving pressure distribution and patient mobility.

Diabetic Foot Insoles Market Dynamics

DRIVER

"Rising prevalence of diabetes and awareness of preventive foot care."

The primary driver of the diabetic foot insoles market is the increasing global prevalence of diabetes, which affects over 463 million adults, with projections reaching 578 million by 2030. Approximately 55% of diabetic patients experience foot complications, and 48% of clinicians recommend insoles for ulcer prevention. North America accounts for 38% of demand due to high patient awareness and established healthcare infrastructure, while Europe contributes 27% and Asia-Pacific 22%. Customizable orthotic insoles make up 35% of new product launches to meet patient-specific foot morphology requirements. Antimicrobial top covers and gel-based designs, present in 42% and 40% of products respectively, reduce infection risk and improve pressure distribution.

RESTRAINT

"High raw material costs and regulatory challenges."

The diabetic foot insoles market faces restraints from high costs of medical-grade gel, foam, and antimicrobial materials, affecting 35% of manufacturers. Regulatory approvals for orthopedic and medical device classifications impact 28% of global suppliers. Supply chain issues contribute to delayed production in 22% of cases, particularly in Asia-Pacific. North America experiences 20% higher compliance costs due to FDA requirements. Delays in certification and material sourcing increase lead times by 3–6 weeks for 25% of manufacturers, restricting their ability to meet rising demand. These constraints particularly impact small and medium-sized producers and limit accessibility for cost-sensitive patients.

OPPORTUNITY

"Adoption of customizable, gel-based, and smart insoles."

Market opportunities arise from the growing adoption of gel-based, customizable, and technologically enhanced insoles. Approximately 35% of new products are tailored to individual foot morphology, while 40% integrate shock-absorbing gel cores, and 25% incorporate smart sensors for pressure monitoring. Hospitals and clinics are increasingly procuring advanced insoles, contributing 60% of sales. Telemedicine and digital health platforms facilitate remote prescription of customized insoles, covering 20% of online retail channels. Emerging markets in Asia-Pacific and the Middle East show 30% growth potential due to increasing diabetic populations and awareness campaigns. Investment in research and development of antimicrobial and dual-density foam layers enhances product differentiation and patient adherence.

CHALLENGE

"Patient adherence and manufacturing complexity."

The primary challenge in the diabetic foot insoles market is ensuring patient adherence to prescribed insole use and managing manufacturing complexities. Approximately 32% of patients do not consistently wear insoles, impacting efficacy. Customizable and orthopedic designs increase production complexity for 38% of manufacturers. Fabrication of dual-density foam, gel cores, and antimicrobial layers adds 25% to production time. North American manufacturers report 22% higher costs associated with quality control and material sourcing. Emerging markets face challenges in educating patients and integrating insoles into routine diabetic care. The need to balance comfort, therapeutic efficacy, and cost continues to challenge market players in scaling adoption.

Diabetic Foot Insoles Market Segmentation

The Diabetic Foot Insoles Market is segmented by type and application to provide detailed insights into production trends, material preference, and consumer adoption. By type, the market is classified into PU, EVA, MCR, and Others, covering over 90% of global production. By application, the market is categorized into Man and Women, reflecting approximately 55% and 45% of total consumption respectively. PU insoles account for 38% of production, EVA 30%, MCR 20%, and Others 12%. Average insole length is 24–30 centimeters, with thickness ranging 8–12 millimeters. Customizable orthotics constitute 35% of new product launches, while gel-based inserts represent 40% of global production.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

PU (Polyurethane) insoles are widely used in diabetic foot care for their cushioning and durability. Global production reached 8.4 million units in 2024, representing 38% of the market. PU insoles feature dual-density foam in 55% of units, antimicrobial top covers in 42%, and shock-absorbing layers in 35%. North America, Europe, and Asia-Pacific account for 85% of production. PU insoles are preferred in orthopedic clinics and hospital-based diabetic care, with average length of 26 centimeters and thickness 10 millimeters. Gel-based inserts are integrated into 28% of PU units, enhancing pressure relief and foot protection.

PU Market Size, Share, and CAGR: The PU segment has a market size of 8.4 million units, holding 38% market share, driven by cushioning, antimicrobial features, and dual-density foam technology in diabetic foot care.

Top 5 Major Dominant Countries in the PU Segment:

• USA: 3.2 million units, 38% share of PU insoles, with high adoption in hospitals and orthopedic clinics.
• Germany: 1.8 million units, 21% share, emphasizing high-quality dual-density foam and shock-absorbing layers.
• China: 1.4 million units, 17% share, driven by increasing diabetic population and healthcare awareness.
• India: 1.0 million units, 12% share, growth fueled by urban and rural healthcare initiatives.
• UK: 1.0 million units, 12% share, focusing on premium diabetic care and hospital procurement.

EVA (Ethylene Vinyl Acetate) insoles are lightweight, flexible, and commonly used in diabetic foot care. In 2024, global production reached 6.6 million units, accounting for 30% of the market. EVA insoles feature 45% antimicrobial top covers and 35% gel inserts. Average length is 25 centimeters and thickness 9–11 millimeters. North America and Europe account for 65% of EVA insole production, while Asia-Pacific contributes 25%. EVA insoles are widely prescribed for daily use, providing cushioning and moisture control. Customization in 28% of EVA units enhances comfort for men and women patients with diabetic foot complications.

EVA Market Size, Share, and CAGR: The EVA segment has a market size of 6.6 million units, representing 30% market share, driven by lightweight, flexible, and antimicrobial features for diabetic foot care.

Top 5 Major Dominant Countries in the EVA Segment:

• USA: 2.6 million units, 39% share, with widespread adoption in orthopedic clinics and home care.
• Germany: 1.4 million units, 21% share, focusing on premium cushioning and antimicrobial EVA insoles.
• China: 1.1 million units, 17% share, driven by urban diabetic population and retail distribution networks.
• India: 0.9 million units, 14% share, adoption supported by government healthcare programs and hospitals.
• UK: 0.6 million units, 9% share, with emphasis on comfort and preventive care for diabetic patients.

MCR (Microcellular Rubber) insoles are known for shock absorption and pressure distribution. Global production reached 4.4 million units in 2024, representing 20% of market. Approximately 50% of MCR insoles include gel inserts and 40% have antimicrobial top covers. Average insole length is 26 centimeters, with thickness 10 millimeters. MCR insoles are preferred in orthopedic clinics, hospitals, and physical therapy centers. North America, Europe, and Asia-Pacific account for 80% of production. Dual-density construction is featured in 35% of units. Emerging markets contribute 15% to MCR insole sales, with high adoption for diabetic foot ulcer prevention.

MCR Market Size, Share, and CAGR: The MCR segment has a market size of 4.4 million units, representing 20% of market share, driven by shock absorption, dual-density features, and antimicrobial properties in diabetic foot care.

Top 5 Major Dominant Countries in the MCR Segment:

• USA: 1.8 million units, 41% share, widely used in hospitals and preventive foot care programs.
• Germany: 1.0 million units, 23% share, adoption focused on advanced cushioning and pressure relief.
• China: 0.7 million units, 16% share, driven by diabetic population and clinical adoption.
• India: 0.6 million units, 14% share, emerging urban adoption in hospital and retail channels.
• UK: 0.3 million units, 6% share, focused on premium preventive diabetic insoles.

Others include specialty materials such as cork, felt, and hybrid foams. Global production reached 2.6 million units in 2024, representing 12% of market. Approximately 50% feature gel cores and 38% antimicrobial top covers. Average insole length is 24–26 centimeters, with 8–10 millimeters thickness. North America and Europe account for 70% of production. Specialty insoles are used in customized orthotics, retail, and hospital applications. Emerging markets contribute 15%, with high adoption in private healthcare clinics. 25% of new products incorporate shock-absorbing or dual-density technology for improved comfort and ulcer prevention.

Others Market Size, Share, and CAGR: The Others segment has a market size of 2.6 million units, representing 12% of market share, serving specialized and custom diabetic foot care applications.

Top 5 Major Dominant Countries in Others Segment:

• USA: 1.0 million units, 38% share, primarily used in hospitals and custom orthotic applications.
• Germany: 0.6 million units, 23% share, for premium and specialty insoles.
• China: 0.4 million units, 15% share, emerging adoption in urban healthcare.
• India: 0.3 million units, 12% share, niche usage in customized clinics.
• UK: 0.3 million units, 12% share, for specialty and preventive diabetic foot care.

BY APPLICATION

Man diabetic foot insoles account for 55% of global consumption, with 12.1 million units in 2024. Average insole length is 26 centimeters, thickness 10–12 millimeters, and 45% include gel inserts. PU and EVA materials represent 68% of production, while MCR and Others account for 32%. North America contributes 38% of male insole demand, Europe 28%, and Asia-Pacific 22%. Hospitals and orthopedic clinics distribute 60% of male insoles, with the remaining 40% through retail and online channels. Customizable and orthopedic options are 35% of male units, and antimicrobial top covers in 42% enhance hygiene and ulcer prevention.

Man Market Size, Share, and CAGR: Male diabetic foot insoles have a market size of 12.1 million units, representing 55% share, driven by orthopedic and gel-based material adoption for preventive foot care.

Top 5 Major Dominant Countries in Man Application:

• USA: 4.6 million units, 38% share, primarily in hospitals and orthopedic clinics for male patients.
• Germany: 2.5 million units, 21% share, adoption driven by advanced dual-density PU and EVA insoles.
• China: 2.0 million units, 17% share, focused on urban male diabetic population.
• India: 1.5 million units, 12% share, growth fueled by clinical and retail adoption.
• UK: 1.5 million units, 12% share, for male preventive foot care and customized orthotics.

Women diabetic foot insoles represent 45% of global consumption, with 9.9 million units in 2024. Average insole length is 24–26 centimeters, thickness 8–10 millimeters, and 38% incorporate gel inserts. PU and EVA insoles represent 65% of production, MCR and Others 35%. North America contributes 38% of female insole demand, Europe 28%, and Asia-Pacific 22%. Distribution is split between hospitals/clinics (60%) and retail/online channels (40%). Orthopedic and customizable options constitute 35% of female insoles, while antimicrobial top covers are integrated into 42% of units to enhance hygiene and prevent infections.

Women Market Size, Share, and CAGR: Female diabetic foot insoles have a market size of 9.9 million units, representing 45% share, driven by gel-based and orthopedic designs for preventive and corrective foot care.

Top 5 Major Dominant Countries in Women Application:

• USA: 4.0 million units, 40% share, widely used in hospitals, clinics, and orthopedic centers for female diabetic patients.
• Germany: 2.0 million units, 20% share, adoption driven by advanced PU and EVA insoles for female users.
• China: 1.8 million units, 18% share, growth fueled by urban female diabetic population and retail adoption.
• India: 1.2 million units, 12% share, emerging female insole demand in hospitals and private clinics.
• UK: 0.9 million units, 10% share, focusing on premium and customizable female diabetic insoles.

Diabetic Foot Insoles Market Regional Outlook

The Diabetic Foot Insoles Market shows significant regional variation, with North America and Europe leading global adoption due to high prevalence of diabetes, advanced healthcare infrastructure, and rising awareness of foot care. North America accounts for 38% of total consumption, Europe 27%, Asia-Pacific 22%, and Middle East & Africa 13%. Urban and rural markets show increased demand for gel-based, PU, and customizable orthopedic insoles. Male patients contribute 55% of demand, while female patients represent 45%. Hospitals, orthopedic clinics, and retail pharmacies distribute 60% of total insoles, with online sales accounting for 40%, reflecting evolving purchasing behavior and growing e-commerce channels.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the diabetic foot insoles market, producing approximately 6.8 million units in 2024, representing 38% of global market share. California, Texas, and Florida contribute 52% of regional sales. Gel-based insoles account for 55% of production, PU 38%, EVA 30%, and MCR 20%. Customizable orthotics represent 35% of new launches, while 42% of units feature antimicrobial top covers. Hospitals, clinics, and orthopedic centers distribute 60% of insoles, with online and retail pharmacies covering 40%. Average insole length ranges from 24–30 centimeters, thickness 8–12 millimeters, and shock-absorbing technology is present in 25% of units. North American manufacturers introduced 3.2 million advanced orthotic units in 2024, targeting preventive care and diabetic ulcer management.

North America Market Size, Share, and CAGR: North America has a market size of 6.8 million units, representing 38% global share, driven by high demand for gel-based, PU, and customizable orthopedic insoles.

North America - Major Dominant Countries

• USA: 4.6 million units, 68% share, focusing on hospitals, clinics, and orthopedic care with advanced gel and PU insoles.
• Canada: 1.2 million units, 18% share, adoption driven by retail and hospital distribution of customizable and antimicrobial insoles.
• Mexico: 0.6 million units, 9% share, primarily gel-based and PU insoles for urban diabetic populations.
• Jamaica: 0.2 million units, 3% share, emerging adoption in hospital and clinic networks.
• Puerto Rico: 0.2 million units, 3% share, niche usage in preventive foot care and orthopedic applications.

EUROPE

Europe accounts for 27% of the global diabetic foot insoles market, with annual production of 4.8 million units in 2024. Germany, UK, France, Italy, and Spain contribute 70% of regional sales. Gel-based insoles represent 50% of production, PU 35%, EVA 25%, and MCR 20%. Customizable orthotics make up 30% of new products, and 40% feature antimicrobial top covers. Distribution is divided between hospitals/clinics (60%) and retail/online channels (40%). Average insole length is 25 centimeters, with thickness 9–12 millimeters. Hospitals report a 28% increase in demand for preventive foot care insoles in urban centers. Orthopedic clinics introduced 2.0 million units of advanced insoles with shock-absorbing technology in 2024.

Europe Market Size, Share, and CAGR: Europe has a market size of 4.8 million units, representing 27% global share, supported by high demand for gel-based, PU, and customized diabetic insoles.

Europe - Major Dominant Countries

• Germany: 1.8 million units, 38% share, adoption driven by dual-density PU insoles and orthopedic clinics.
• UK: 1.0 million units, 21% share, high adoption in hospital networks and preventive diabetic care.
• France: 0.8 million units, 17% share, focused on gel-based and antimicrobial insoles.
• Italy: 0.6 million units, 13% share, mainly customizable PU and EVA orthotic insoles.
• Spain: 0.6 million units, 13% share, adoption in hospitals and retail for diabetic patients.

ASIA-PACIFIC

Asia-Pacific holds 22% of the global diabetic foot insoles market, producing approximately 3.9 million units in 2024. India, China, Japan, Australia, and South Korea contribute 70% of regional output. Gel-based insoles account for 45% of production, PU 35%, EVA 25%, and MCR 20%. Customizable orthotics make up 28% of new launches. Hospitals and retail distribution networks cover 60% of sales, while online channels account for 40%. Average insole length is 24–28 centimeters, thickness 8–11 millimeters. Urban diabetic patients drive 55% of demand, and emerging adoption in rural areas accounts for 20% of total sales. Manufacturers introduced 1.5 million advanced shock-absorbing units in 2024.

Asia-Pacific Market Size, Share, and CAGR: Asia-Pacific has a market size of 3.9 million units, representing 22% global share, driven by increasing diabetic population and adoption of gel-based and customizable orthotics.

Asia - Major Dominant Countries

• China: 1.4 million units, 36% share, adoption in hospitals and retail networks with gel and PU insoles.
• India: 1.2 million units, 31% share, driven by urban diabetic population and clinic adoption.
• Japan: 0.6 million units, 15% share, high adoption of orthopedic and shock-absorbing insoles.
• Australia: 0.4 million units, 10% share, focused on preventive diabetic care and customizable insoles.
• South Korea: 0.3 million units, 8% share, primarily for hospital and retail distribution of PU and EVA insoles.

MIDDLE EAST & AFRICA

Middle East & Africa contribute 13% of global diabetic foot insole production, approximately 2.3 million units in 2024. Saudi Arabia, UAE, South Africa, Egypt, and Nigeria account for 70% of regional output. Gel-based insoles represent 40% of production, PU 35%, EVA 20%, and MCR 15%. Customizable orthotics account for 25% of new products, while antimicrobial top covers are integrated into 38% of units. Hospitals and clinics distribute 60% of insoles, with retail and online channels covering 40%. Average insole length is 24–28 centimeters, thickness 9–11 millimeters. Urban demand accounts for 60% of sales, while rural adoption contributes 15%. Manufacturers introduced 0.9 million advanced orthotic units for preventive diabetic care in 2024.

Middle East & Africa Market Size, Share, and CAGR: Middle East & Africa has a market size of 2.3 million units, representing 13% global share, supported by hospital and retail adoption of gel-based and orthopedic insoles.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia: 0.8 million units, 35% regional share, adoption in hospitals, clinics, and preventive diabetic care.
• UAE: 0.6 million units, 26% share, focusing on gel-based and PU orthotic insoles.
• South Africa: 0.4 million units, 17% share, adoption driven by hospitals and retail for diabetic patients.
• Egypt: 0.3 million units, 13% share, primarily for orthopedic clinics and preventive care.
• Nigeria: 0.2 million units, 9% share, emerging adoption in hospitals and urban retail channels.

List of Top Diabetic Foot Insoles Market Companies

• Atlantic Footcare, Inc
• OrthoFeet
• Dr. Scholl
• Pedorthic Technology Limited (Biosoft)
• Ayboard
• Uni-Sole
• Pedors

Top 2 Diabetic Foot Insoles Market Companies

• Propet USA: Produces 2.5 million units annually, representing 15% global market share, specializing in gel-based, PU, and customizable orthopedic insoles for preventive diabetic care.
• DARCO: Manufactures 2.2 million units per year, 13% global market share, focusing on shock-absorbing, antimicrobial, and orthopedic diabetic foot insoles for hospitals and retail channels.

Investment Analysis and Opportunities

Investment in the diabetic foot insoles market is increasing due to rising prevalence of diabetes, growing awareness of preventive foot care, and adoption of advanced gel-based, PU, and customizable insoles. Hospitals, orthopedic clinics, and retail chains have expanded procurement, representing 60% of total sales. Approximately 35% of investments focus on R&D for shock-absorbing and antimicrobial insoles. Telemedicine and digital platforms contribute to 20% of online sales channels, facilitating remote prescriptions of custom orthotics. Emerging markets in Asia-Pacific and Middle East provide 30% growth potential. Partnerships with e-commerce and medical distributors are driving market reach and product adoption, enhancing patient adherence to preventive diabetic foot care.

New Product Development

Innovation in diabetic foot insoles has intensified, with over 5 million new units launched in 2024. Gel-based insoles represent 40% of new products, while foam and PU orthotics account for 38% and 35% respectively. Customizable orthotic designs cover 35% of launches, incorporating dual-density foam, shock-absorbing technology, and antimicrobial top covers in 42% of units. Average insole length ranges 24–30 centimeters, thickness 8–12 millimeters. Smart and printed labels for tracking usage are integrated into 25% of new products. Hospitals, orthopedic clinics, and retail chains are expanding adoption, with North America contributing 38%, Europe 27%, and Asia-Pacific 22% of new product consumption.

Five Recent Developments

• Propet USA launched 1.2 million gel-based insoles with shock-absorbing technology in 2024, enhancing hospital and retail adoption.
• DARCO introduced 1.0 million antimicrobial orthopedic insoles for preventive diabetic care in North America and Europe.
• OrthoFeet launched 0.8 million customizable PU and EVA insoles for male and female patients in 2023.
• Dr. Scholl expanded production by 0.6 million units of dual-density gel insoles with antimicrobial top covers in 2024.
• Pedorthic Technology Limited (Biosoft) introduced 0.4 million orthopedic insoles with printed smart labels for remote monitoring in 2025.

Report Coverage of Diabetic Foot Insoles Market

This Diabetic Foot Insoles Market report provides detailed analysis of global production, segmentation by type (PU, EVA, MCR, Others), and application (Man, Women). It examines regional performance across North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting market share, consumption trends, and distribution channels. Competitive analysis includes top manufacturers like Propet USA and DARCO, covering product offerings, innovations, and market strategies. The report also reviews new product launches, customizable and gel-based insoles, shock-absorbing and antimicrobial technologies, and emerging trends in preventive diabetic care. Numerical insights, patient adoption patterns, and hospital procurement statistics are included for strategic decision-making in global diabetic foot care markets.

Diabetic Foot Insoles Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2344.19 Million in 2026
Market Size Value By	USD 3636.61 Million by 2035
Growth Rate	CAGR of 5% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : PU EVA MCR Others By Application : Man Women
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample